Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0014-2964(80)90036-5 | DOI Listing |
Anal Chem
December 2024
State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, China.
Enzyme Microb Technol
February 2025
Chemical Analysis and Biosensors Research Group, Laboratory of Process Engineering and Environment, Faculty of Sciences and Techniques, Hassan II University of Casablanca, Morocco. Electronic address:
Turk J Pharm Sci
November 2024
Alberta University Faculty of Engineering, Department of Chemical and Materials Engineering, Alberta, Canada.
Objectives: Breast cancer is the most common type of cancer among women and the second most common cause of death after lung cancer. The inhibitor of growth (ING) transcript levels are often suppressed in cancer cells, making it a promising candidate for cancer therapy. In this study, we aimed to formulate a polyplex that effectively carries and delivers pING4 to breast cancer cells.
View Article and Find Full Text PDFBMC Nephrol
November 2024
Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Background: Karyomegalic interstitial nephritis (KIN) is a rare renal diagnosis associated with both genetic and medication etiologies. The primary gene associated with KIN is the FAN1 gene which encodes a protein responsible for DNA interstrand repair. Common medication triggers of KIN are chemotherapeutic agents, especially those which disrupt DNA structure such as carboplatin.
View Article and Find Full Text PDFDokl Biochem Biophys
October 2024
Joint-Stock Company GENERIUM (JSC GENERIUM), Volginskii settlement, 601125, Petushinskii district, Vladimir oblast, Russia.
The article presents the results of studies of the drug Tigerase® (inhalation solution manufactured by JSC GENERIUM, Russia), conducted to obtain evidence of its similarity (comparability) to the reference drug Pulmozyme® (inhalation solution, manufactured by Hoffmann-La Roche Ltd., Switzerland). Both drugs contain human recombinant deoxyribonuclease I (dornase alfa) as an active substance and are intended for the treatment of cystic fibrosis with pulmonary manifestations (mucoviscidosis).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!